LV12719B - Benzoksazinons kā hiv apgrieztās transkriptāzes inhibitors - Google Patents

Benzoksazinons kā hiv apgrieztās transkriptāzes inhibitors Download PDF

Info

Publication number: LV12719B
Authority: LV; Latvia
Prior art keywords: chloro; dihydro; benzoxazin; trifluoromethyl; optionally substituted
Prior art date: 1992-08-07

Application number

LVP-01-87A

Other languages

English (en)

Latvian (lv)

Other versions

LV12719A (lv

Inventor

Steven D. Young

Lekhanh O. Tran

Susan F. BRITCHER

Jr. William C. LUMMA

Linda S. Payne

Original Assignee

Merck & Co., Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-07

Filing date

2001-06-01

Publication date

2001-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12719(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-06-01 Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.

2001-09-20 Publication of LV12719A publication Critical patent/LV12719A/xx

2001-12-20 Publication of LV12719B publication Critical patent/LV12719B/lv

Links

HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 63
208000030507 AIDS Diseases 0.000 claims abstract description 55
108010078851 HIV Reverse Transcriptase Proteins 0.000 claims abstract description 15
239000003814 drug Substances 0.000 claims abstract description 15
230000002401 inhibitory effect Effects 0.000 claims abstract description 8
-1 acenaphthyl Chemical group 0.000 claims description 58
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 22
238000011282 treatment Methods 0.000 claims description 18
125000000217 alkyl group Chemical group 0.000 claims description 17
125000000623 heterocyclic group Chemical group 0.000 claims description 17
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
239000003112 inhibitor Substances 0.000 claims description 15
125000001624 naphthyl group Chemical group 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 15
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 15
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 14
238000000034 method Methods 0.000 claims description 14
125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 13
208000031886 HIV Infections Diseases 0.000 claims description 12
239000004305 biphenyl Substances 0.000 claims description 11
235000010290 biphenyl Nutrition 0.000 claims description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
208000037357 HIV infectious disease Diseases 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 10
229920006395 saturated elastomer Polymers 0.000 claims description 10
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims description 9
125000000753 cycloalkyl group Chemical group 0.000 claims description 9
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 8
125000005843 halogen group Chemical group 0.000 claims description 7
125000005842 heteroatom Chemical group 0.000 claims description 6
DRPGAFHTQXUJMY-UHFFFAOYSA-N 6-chloro-4-(2-phenylethynyl)-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one Chemical compound O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1=CC=CC=C1 DRPGAFHTQXUJMY-UHFFFAOYSA-N 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
125000003342 alkenyl group Chemical group 0.000 claims description 5
230000000840 anti-viral effect Effects 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
125000002950 monocyclic group Chemical group 0.000 claims description 5
230000003287 optical effect Effects 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
230000004071 biological effect Effects 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
125000004953 trihalomethyl group Chemical group 0.000 claims description 3
GVZVDZMVHZPNBD-UHFFFAOYSA-N 7-(chloromethyl)-1,7-dimethylbicyclo[2.2.1]heptane Chemical group CC1(CCl)C2CCC1(C)CC2 GVZVDZMVHZPNBD-UHFFFAOYSA-N 0.000 claims description 2
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 3
229940127073 nucleoside analogue Drugs 0.000 claims 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
208000012124 AIDS-related disease Diseases 0.000 claims 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 1
238000000926 separation method Methods 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 11
238000002360 preparation method Methods 0.000 abstract description 5
VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 64
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
239000000243 solution Substances 0.000 description 52
241000725303 Human immunodeficiency virus Species 0.000 description 31
239000000203 mixture Substances 0.000 description 30
206010001513 AIDS related complex Diseases 0.000 description 29
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 28
229960002555 zidovudine Drugs 0.000 description 27
235000019439 ethyl acetate Nutrition 0.000 description 26
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
239000002904 solvent Substances 0.000 description 17
239000012267 brine Substances 0.000 description 16
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
239000007787 solid Substances 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 12
229910052786 argon Inorganic materials 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
239000003921 oil Substances 0.000 description 11
239000000460 chlorine Substances 0.000 description 10
238000001035 drying Methods 0.000 description 10
239000000463 material Substances 0.000 description 10
238000005160 1H NMR spectroscopy Methods 0.000 description 9
208000007766 Kaposi sarcoma Diseases 0.000 description 9
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
238000003756 stirring Methods 0.000 description 9
239000003443 antiviral agent Substances 0.000 description 8
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 8
YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 8
238000001914 filtration Methods 0.000 description 8
238000010992 reflux Methods 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
102100031780 Endonuclease Human genes 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000009835 boiling Methods 0.000 description 6
239000013078 crystal Substances 0.000 description 6
239000002955 immunomodulating agent Substances 0.000 description 6
229940121354 immunomodulator Drugs 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical compound C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 5
241000700605 Viruses Species 0.000 description 5
125000000304 alkynyl group Chemical group 0.000 description 5
229940121357 antivirals Drugs 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
NUBQKPWHXMGDLP-BDEHJDMKSA-N indinavir sulfate Chemical compound OS(O)(=O)=O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 NUBQKPWHXMGDLP-BDEHJDMKSA-N 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
MHUVLRNBDLFMHQ-UHFFFAOYSA-N 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-1h-pyridin-2-one Chemical compound O=C1NC(C)=C(CC)C=C1CCC1=NC2=CC=CC=C2O1 MHUVLRNBDLFMHQ-UHFFFAOYSA-N 0.000 description 4
241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
125000002883 imidazolyl group Chemical group 0.000 description 4
239000002777 nucleoside Substances 0.000 description 4
150000003833 nucleoside derivatives Chemical class 0.000 description 4
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
239000000725 suspension Substances 0.000 description 4
102000003390 tumor necrosis factor Human genes 0.000 description 4
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108010092408 Eosinophil Peroxidase Proteins 0.000 description 3
102100031939 Erythropoietin Human genes 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
108010027044 HIV Core Protein p24 Proteins 0.000 description 3
108010010369 HIV Protease Proteins 0.000 description 3
229910004298 SiO 2 Inorganic materials 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
235000019270 ammonium chloride Nutrition 0.000 description 3
230000002924 anti-infective effect Effects 0.000 description 3
229960005475 antiinfective agent Drugs 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
239000012043 crude product Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
229940042443 other antivirals in atc Drugs 0.000 description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
PAXWODJTHKJQDZ-VHSXEESVSA-N (1r,4s)-1,7,7-trimethyl-2-oxo-3-oxabicyclo[2.2.1]heptane-4-carbonyl chloride Chemical compound C1C[C@]2(C(Cl)=O)OC(=O)[C@@]1(C)C2(C)C PAXWODJTHKJQDZ-VHSXEESVSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
NOKSRMDODJGCPZ-UHFFFAOYSA-N 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoroethanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C(F)(F)F NOKSRMDODJGCPZ-UHFFFAOYSA-N 0.000 description 2
HDMHBHNRWDNNCD-UHFFFAOYSA-N 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine Chemical compound OCCOCN1C(=O)NC(=O)C(C)=C1SC1=CC=CC=C1 HDMHBHNRWDNNCD-UHFFFAOYSA-N 0.000 description 2
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
MAZOKIJIPGIFQC-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-1,1,1-trifluoro-4-phenylbut-3-yn-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(C(F)(F)F)C#CC1=CC=CC=C1 MAZOKIJIPGIFQC-UHFFFAOYSA-N 0.000 description 2
KEMUGFRERPPUHB-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(C(F)(F)F)C#CC1CC1 KEMUGFRERPPUHB-UHFFFAOYSA-N 0.000 description 2
RLLFRFBCKFLKNL-UHFFFAOYSA-N 2-[6-chloro-1-ethynyl-2-oxo-4-(trifluoromethyl)-3,1-benzoxazin-4-yl]benzonitrile Chemical compound O1C(=O)N(C#C)C2=CC=C(Cl)C=C2C1(C(F)(F)F)C1=CC=CC=C1C#N RLLFRFBCKFLKNL-UHFFFAOYSA-N 0.000 description 2
QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 2
VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
QKFXVPYWSZJIMC-UHFFFAOYSA-N 6-chloro-4-ethynyl-4-(trifluoromethyl)-1h-3,1-benzoxazin-2-one Chemical compound C1=C(Cl)C=C2C(C(F)(F)F)(C#C)OC(=O)NC2=C1 QKFXVPYWSZJIMC-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
MGDDZCOWYQRGKK-UHFFFAOYSA-N C1=CC=C(C=C1)CCC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F Chemical compound C1=CC=C(C=C1)CCC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F MGDDZCOWYQRGKK-UHFFFAOYSA-N 0.000 description 2
206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 2
229960005327 acemannan Drugs 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
208000001763 cytomegalovirus retinitis Diseases 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
229950007919 egtazic acid Drugs 0.000 description 2
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000006260 foam Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
JGZKUKYUQJUUNE-UHFFFAOYSA-L magnesium;ethoxyethane;dibromide Chemical compound [Mg+2].[Br-].[Br-].CCOCC JGZKUKYUQJUUNE-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
235000010603 pastilles Nutrition 0.000 description 2
YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 description 2
229960001624 pentamidine isethionate Drugs 0.000 description 2
201000003450 persistent generalized lymphadenopathy Diseases 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
238000001665 trituration Methods 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
KPWKPGFLZGMMFX-VHSXEESVSA-N (-)-camphanic acid Chemical compound C1C[C@]2(C(O)=O)OC(=O)[C@@]1(C)C2(C)C KPWKPGFLZGMMFX-VHSXEESVSA-N 0.000 description 1
FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
125000004227 1,3-benzoxazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)OC2=C1[H] 0.000 description 1
UBDAXLZWFPTBKC-UHFFFAOYSA-N 1-(2-amino-5-chlorophenyl)-2-chloro-2,2-difluoroethanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C(F)(F)Cl UBDAXLZWFPTBKC-UHFFFAOYSA-N 0.000 description 1
YBPWZWXKZDKBLQ-UHFFFAOYSA-N 1-(2-amino-5-chlorophenyl)-3-fluoro-2,2-bis(fluoromethyl)propan-1-one Chemical compound NC1=CC=C(Cl)C=C1C(=O)C(CF)(CF)CF YBPWZWXKZDKBLQ-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
JVTSHOJDBRTPHD-UHFFFAOYSA-N 2,2,2-trifluoroacetaldehyde Chemical compound FC(F)(F)C=O JVTSHOJDBRTPHD-UHFFFAOYSA-N 0.000 description 1
SENLZSXKQUSKOS-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-1,1,1-trifluorobut-3-yn-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(C#C)C(F)(F)F SENLZSXKQUSKOS-UHFFFAOYSA-N 0.000 description 1
WWIRSVDDUFBDSN-UHFFFAOYSA-N 2-(2-amino-5-chlorophenyl)-1,1,1-trifluorohex-5-en-2-ol Chemical compound NC1=CC=C(Cl)C=C1C(O)(CCC=C)C(F)(F)F WWIRSVDDUFBDSN-UHFFFAOYSA-N 0.000 description 1
LJXGLQWLORNQQY-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid;3,6-dichloro-2-methoxybenzoic acid;n-methylmethanamine Chemical compound CNC.CNC.COC1=C(Cl)C=CC(Cl)=C1C(O)=O.OC(=O)C(C)OC1=CC=C(Cl)C=C1C LJXGLQWLORNQQY-UHFFFAOYSA-N 0.000 description 1
ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JDDAFHUEOVUDFJ-UHFFFAOYSA-N 2-iodobenzonitrile Chemical compound IC1=CC=CC=C1C#N JDDAFHUEOVUDFJ-UHFFFAOYSA-N 0.000 description 1
125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical group C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
VTSFNCCQCOEPKF-UHFFFAOYSA-N 3-amino-1h-pyridin-2-one Chemical class NC1=CC=CN=C1O VTSFNCCQCOEPKF-UHFFFAOYSA-N 0.000 description 1
BPEBREXIBXVMCY-UHFFFAOYSA-N 4,7-dichloro-1,3-benzoxazole Chemical compound ClC1=CC=C(Cl)C2=C1N=CO2 BPEBREXIBXVMCY-UHFFFAOYSA-N 0.000 description 1
WGCSRACJKNFMEF-UHFFFAOYSA-N 4-(trifluoromethyl)-1,4-dihydro-3,1-benzoxazin-2-one Chemical compound C1=CC=C2C(C(F)(F)F)OC(=O)NC2=C1 WGCSRACJKNFMEF-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
DMAYBPBPEUFIHJ-UHFFFAOYSA-N 4-bromobut-1-ene Chemical compound BrCCC=C DMAYBPBPEUFIHJ-UHFFFAOYSA-N 0.000 description 1
VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
BTDQPCCLRKPPNW-CWLBMTPASA-N 6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1-[(4s)-4,7,7-trimethylbicyclo[2.2.1]heptane-3-carbonyl]-3,1-benzoxazin-2-one Chemical compound C1([C@]2(C)CCC(C1)C2(C)C)C(=O)N(C1=CC=C(Cl)C=C11)C(=O)OC1(C(F)(F)F)C#CC1CC1 BTDQPCCLRKPPNW-CWLBMTPASA-N 0.000 description 1
BQFHOKSTYVECBF-UHFFFAOYSA-N 6-chloro-4-[chloro(difluoro)methyl]-4-(2-phenylethynyl)-1h-3,1-benzoxazin-2-one Chemical compound O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(Cl)F)C#CC1=CC=CC=C1 BQFHOKSTYVECBF-UHFFFAOYSA-N 0.000 description 1
VASAMHJOSWRNRO-UHFFFAOYSA-N 6-chloro-4-cyclopropyl-1-ethynyl-4-(trifluoromethyl)-3,1-benzoxazin-2-one Chemical compound O1C(=O)N(C#C)C2=CC=C(Cl)C=C2C1(C(F)(F)F)C1CC1 VASAMHJOSWRNRO-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000032484 Accidental exposure to product Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000427202 Adria Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003581 Asymptomatic HIV infection Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
208000006081 Cryptococcal meningitis Diseases 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
206010011831 Cytomegalovirus infection Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010068370 Glutens Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
238000007341 Heck reaction Methods 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
108010054710 IMREG-1 Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010069803 Injury associated with device Diseases 0.000 description 1
102100020873 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
ITATYELQCJRCCK-UHFFFAOYSA-N Mandelic Acid, Methyl Ester Chemical compound COC(=O)C(O)C1=CC=CC=C1 ITATYELQCJRCCK-UHFFFAOYSA-N 0.000 description 1
238000006683 Mannich reaction Methods 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010027209 Meningitis cryptococcal Diseases 0.000 description 1
YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
108010042237 Methionine Enkephalin Proteins 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
208000007027 Oral Candidiasis Diseases 0.000 description 1
108010071384 Peptide T Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
239000004187 Spiramycin Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
101800001703 Thymopentin Proteins 0.000 description 1
102400000160 Thymopentin Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000005130 benzoxazines Chemical class 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
GKPOMITUDGXOSB-UHFFFAOYSA-N but-3-yn-2-ol Chemical compound CC(O)C#C GKPOMITUDGXOSB-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125961 compound 24 Drugs 0.000 description 1
229940126540 compound 41 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000007771 core particle Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940087451 cytovene Drugs 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229940116901 diethyldithiocarbamate Drugs 0.000 description 1
IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
238000003810 ethyl acetate extraction Methods 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
NPTDXPDGUHAFKC-UHFFFAOYSA-N ethynylcyclopropane Chemical group C#CC1CC1 NPTDXPDGUHAFKC-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
235000021312 gluten Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
102000044890 human EPO Human genes 0.000 description 1
150000003949 imides Chemical class 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000006263 metalation reaction Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
210000000110 microvilli Anatomy 0.000 description 1
JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
229960005225 mifamurtide Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
IZISMXMXCLUHGI-UHFFFAOYSA-N n-(4-chlorophenyl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=C(Cl)C=C1 IZISMXMXCLUHGI-UHFFFAOYSA-N 0.000 description 1
QJQAMHYHNCADNR-UHFFFAOYSA-N n-methylpropanamide Chemical compound CCC(=O)NC QJQAMHYHNCADNR-UHFFFAOYSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229950001030 piritrexim Drugs 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
101150088264 pol gene Proteins 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
229960005179 primaquine Drugs 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
108700018720 recombinant interferon alpha 2b-like Proteins 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229940064914 retrovir Drugs 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000002976 reverse transcriptase assay Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
229960000885 rifabutin Drugs 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
235000019372 spiramycin Nutrition 0.000 description 1
229960001294 spiramycin Drugs 0.000 description 1
229930191512 spiramycin Natural products 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
229960004517 thymopentin Drugs 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
229960001099 trimetrexate Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
238000007514 turning Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
229940100050 virazole Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heat Sensitive Colour Forming Recording (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LVP-01-87A 1992-08-07 2001-06-01 Benzoksazinons kā hiv apgrieztās transkriptāzes inhibitors LV12719B (lv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92660792A	1992-08-07	1992-08-07
US5480593A	1993-04-27	1993-04-27

Publications (2)

Publication Number	Publication Date
LV12719A LV12719A (lv)	2001-09-20
LV12719B true LV12719B (lv)	2001-12-20

Family

ID=26733517

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-01-87A LV12719B (lv)	1992-08-07	2001-06-01	Benzoksazinons kā hiv apgrieztās transkriptāzes inhibitors

Country Status (36)

Country	Link
EP (1)	EP0582455B1 (fr)
JP (1)	JPH0780860B2 (fr)
KR (1)	KR100272387B1 (fr)
CN (3)	CN1318031C (fr)
AT (1)	ATE197295T1 (fr)
AU (1)	AU670300B2 (fr)
BG (1)	BG62612B1 (fr)
CA (1)	CA2101572C (fr)
CZ (1)	CZ290447B6 (fr)
DE (4)	DE122008000034I1 (fr)
DK (1)	DK0582455T3 (fr)
DZ (1)	DZ1707A1 (fr)
ES (1)	ES2151897T3 (fr)
FI (2)	FI115457B (fr)
GR (1)	GR3034754T3 (fr)
HR (1)	HRP931102B1 (fr)
HU (1)	HU223076B1 (fr)
IL (1)	IL106507A (fr)
LU (2)	LU90709I2 (fr)
LV (1)	LV12719B (fr)
MX (1)	MX192812B (fr)
MY (1)	MY109834A (fr)
NL (2)	NL300032I2 (fr)
NO (3)	NO304886B1 (fr)
NZ (1)	NZ255216A (fr)
PL (2)	PL176679B1 (fr)
PT (1)	PT582455E (fr)
RO (1)	RO113641B1 (fr)
RU (1)	RU2186775C2 (fr)
SG (1)	SG52698A1 (fr)
SI (1)	SI9300419B (fr)
SK (1)	SK282276B6 (fr)
TW (2)	TW382014B (fr)
UA (1)	UA42699C2 (fr)
WO (1)	WO1994003440A1 (fr)
YU (1)	YU49439B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5633405A (en) *	1995-05-25	1997-05-27	Merck & Co., Inc.	Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
US6147210A (en)	1996-07-26	2000-11-14	Dupont Pharmaceuticals Company	Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
AU3736197A (en) *	1996-07-26	1998-02-20	Du Pont Pharmaceuticals Company	A practical synthesis of benzoxazinones useful as hiv reverse transcripta se inhibitors
ZA9711256B (en)	1996-12-16	1999-06-15	Du Pont Merck Pharma	Asymmetric synthesis of benzoxazinones
US5932726A (en) *	1996-12-16	1999-08-03	Dupont Pharmaceuticals Company	Asymmetric synthesis of benzoxazinones
US5965729A (en)	1997-02-05	1999-10-12	Merck & Co., Inc.	Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
DE69841972D1 (de) *	1997-02-05	2010-12-09	Merck Sharp & Dohme	Verfahren zur kristallisation eines reverstranskriptase-inhibitors, bei welchem ein anti-lösungsmittel benutzt wird
CA2285000A1 (fr) *	1997-04-07	1998-10-15	Dupont Pharmaceuticals Company	Synthese asymetrique de benzoxazinones via de nouveaux intermediaires
US6124302A (en) *	1997-04-09	2000-09-26	Dupont Pharmaceuticals	4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
PL338894A1 (en) *	1997-09-03	2000-11-20	Merck & Co Inc	Method of increasing optical purity of 2r-[1-hydroxy-1-trifluoromethy-3-cyclopropylopropin-2-yl]-4-chloroaniline
US5952528A (en) *	1997-09-03	1999-09-14	Merck & Co., Inc.	Process for enhancing the optical purity
US20010014352A1 (en)	1998-05-27	2001-08-16	Udit Batra	Compressed tablet formulation
HRP990182A2 (en) *	1998-06-11	2000-02-29	Du Pont Pharm Co	Crystalline efavirenz
US6673372B1 (en)	1998-06-11	2004-01-06	Bristol-Myers Squibb Pharma Company	Crystalline Efavirenz
WO2000000475A1 (fr) *	1998-06-30	2000-01-06	Du Pont Pharmaceuticals Company	Quinoline-2(1h)-ones substituees utiles comme inhibiteurs de la transcriptase inverse du vih
US6509334B1 (en)	1999-05-04	2003-01-21	American Home Products Corporation	Cyclocarbamate derivatives as progesterone receptor modulators
SE9904652D0 (sv) *	1999-12-17	1999-12-17	Astra Pharma Prod	Novel Compounds
UA73119C2 (en)	2000-04-19	2005-06-15	American Home Products Corpoir	Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6946469B2 (en)	2001-03-28	2005-09-20	Bristol-Myers Squibb Pharma Company	Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
WO2004085406A1 (fr)	2003-03-24	2004-10-07	F. Hoffmann-La Roche Ag	Benzyl-pyridazinones en tant qu'inhibiteurs de transcriptase inverse
AR048650A1 (es) *	2004-05-04	2006-05-10	Tibotec Pharm Ltd	Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
AR056652A1 (es) *	2005-04-11	2007-10-17	Tibotec Pharm Ltd	Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
WO2009044788A1 (fr) *	2007-10-05	2009-04-09	Banyu Pharmaceutical Co., Ltd.	Dérivé de benzoxazinone
GB0720503D0 (en)	2007-10-22	2007-11-28	Angeletti P Ist Richerche Bio	New compound
WO2011000532A2 (fr)	2009-07-03	2011-01-06	Archimica Gmbh	Procédé daddition énantiosélective de nucléophiles carbonés organométalliques sur des trifluorométhylcétones et utilisation du procédé dans la synthèse dinhibiteurs de la transcriptase inverse du vih
EP3351249A1 (fr)	2010-01-27	2018-07-25	VIIV Healthcare Company	Thérapie antivirale
EP2471783A1 (fr)	2010-12-23	2012-07-04	Esteve Química, S.A.	Nouvelle forme polymorphe de l'éfavirenz
CN103664816B (zh) *	2011-01-06	2016-03-02	中国科学院上海有机化学研究所	Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) *	2011-03-15	2015-02-18	中国科学院上海有机化学研究所	一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
JP7071036B2 (ja)	2019-02-15	2022-05-18	福建永晶科技股▲ふん▼有限公司	Ｆｒｉｅｄｅｌ－Ｃｒａｆｔｓ反応の新しい新方法及び当該方法に用いられる触媒
CN110372625B (zh) *	2019-08-06	2022-11-01	常州大学	蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) *	2021-04-14	2022-02-18	南京工业大学	一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
EP4416134A4 (fr) *	2021-10-15	2025-09-10	Merck Sharp & Dohme Llc	Dérivés de benzoxazinone utilisés comme agents cytotoxiques sélectifs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3526621A (en) *	1966-08-03	1970-09-01	Farmaceutical Italia Soc	Substituted 3,1-benzoxazin-2-one
US3562621A (en) *	1967-07-26	1971-02-09	Technipower Inc	Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) *	1982-05-06	1983-11-10	Dr. Karl Thomae Gmbh, 7950 Biberach	Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (fr) *	1989-12-18	1991-06-19	Wayne J. Thompson	Inhibiteurs de la protease du vih utiles dans le traitement du sida
IL99843A0 (en) *	1990-11-01	1992-08-18	Merck & Co Inc	Synergistic combination of hiv reverse transcriptase inhibitors

1993
- 1993-07-28 IL IL106507A patent/IL106507A/xx not_active IP Right Cessation
- 1993-07-29 CA CA002101572A patent/CA2101572C/fr not_active Expired - Lifetime
- 1993-08-03 ES ES93306114T patent/ES2151897T3/es not_active Expired - Lifetime
- 1993-08-03 DE DE122008000034C patent/DE122008000034I1/de active Pending
- 1993-08-03 DE DE69329608T patent/DE69329608T2/de not_active Expired - Lifetime
- 1993-08-03 PT PT93306114T patent/PT582455E/pt unknown
- 1993-08-03 DE DE2001199013 patent/DE10199013I1/de active Pending
- 1993-08-03 AT AT93306114T patent/ATE197295T1/de active
- 1993-08-03 DE DE1993629608 patent/DE10199013I2/de active Active
- 1993-08-03 DK DK93306114T patent/DK0582455T3/da active
- 1993-08-03 MY MYPI93001523A patent/MY109834A/en unknown
- 1993-08-03 SG SG1996008032A patent/SG52698A1/en unknown
- 1993-08-03 EP EP93306114A patent/EP0582455B1/fr not_active Expired - Lifetime
- 1993-08-04 TW TW082106237A patent/TW382014B/zh not_active IP Right Cessation
- 1993-08-04 DZ DZ930090A patent/DZ1707A1/fr active
- 1993-08-04 TW TW088117982A patent/TWI233436B/zh not_active IP Right Cessation
- 1993-08-05 MX MX9304775A patent/MX192812B/es not_active IP Right Cessation
- 1993-08-05 YU YU53093A patent/YU49439B/sh unknown
- 1993-08-05 JP JP5194727A patent/JPH0780860B2/ja not_active Expired - Lifetime
- 1993-08-06 CZ CZ1995286A patent/CZ290447B6/cs not_active IP Right Cessation
- 1993-08-06 HU HU9500366A patent/HU223076B1/hu active Protection Beyond IP Right Term
- 1993-08-06 HR HR931102A patent/HRP931102B1/xx not_active IP Right Cessation
- 1993-08-06 UA UA95028099A patent/UA42699C2/uk unknown
- 1993-08-06 NZ NZ255216A patent/NZ255216A/en not_active IP Right Cessation
- 1993-08-06 SK SK161-95A patent/SK282276B6/sk active Protection Beyond IP Right Term
- 1993-08-06 RU RU95107403/04A patent/RU2186775C2/ru active
- 1993-08-06 KR KR1019950700472A patent/KR100272387B1/ko not_active Expired - Lifetime
- 1993-08-06 RO RO95-00190A patent/RO113641B1/ro unknown
- 1993-08-06 PL PL93325950A patent/PL176679B1/pl unknown
- 1993-08-06 AU AU44496/93A patent/AU670300B2/en not_active Expired
- 1993-08-06 CN CNB991181085A patent/CN1318031C/zh not_active Expired - Lifetime
- 1993-08-06 PL PL93307348A patent/PL175615B1/pl unknown
- 1993-08-06 CN CN93117660A patent/CN1051767C/zh not_active Expired - Lifetime
- 1993-08-06 WO PCT/US1993/007376 patent/WO1994003440A1/fr not_active Ceased
- 1993-08-06 SI SI9300419A patent/SI9300419B/sl unknown
1995
- 1995-01-30 BG BG99383A patent/BG62612B1/bg unknown
- 1995-02-06 FI FI950508A patent/FI115457B/fi not_active IP Right Cessation
- 1995-02-06 NO NO950424A patent/NO304886B1/no active Protection Beyond IP Right Term
1998
- 1998-10-10 CN CN98121309A patent/CN1107505C/zh not_active Expired - Lifetime
2000
- 2000-06-16 NO NO2000004C patent/NO2000004I1/no unknown
- 2000-11-03 GR GR20000402341T patent/GR3034754T3/el unknown
- 2000-12-08 NL NL300032C patent/NL300032I2/nl unknown
- 2000-12-20 LU LU90709C patent/LU90709I2/fr unknown
2001
- 2001-06-01 LV LVP-01-87A patent/LV12719B/lv unknown
2004
- 2004-02-27 FI FI20040309A patent/FI20040309A7/fi unknown
2008
- 2008-05-15 NL NL300347C patent/NL300347I1/nl unknown
- 2008-05-27 LU LU91446C patent/LU91446I2/fr unknown
- 2008-06-12 NO NO2008008C patent/NO2008008I1/no unknown

Also Published As

Publication number	Publication date
HRP931102A2 (en)	1997-10-31
LU90709I2 (fr)	2002-02-04
SI9300419A (en)	1994-06-30
SG52698A1 (en)	1998-09-28
NZ255216A (en)	1996-05-28
BG62612B1 (bg)	2000-03-31
TW382014B (en)	2000-02-11
DK0582455T3 (da)	2000-11-27
SI9300419B (sl)	2002-10-31
EP0582455A1 (fr)	1994-02-09
NO2008008I1 (no)	2008-06-30
EP0582455B1 (fr)	2000-11-02
CN1221608A (zh)	1999-07-07
CN1107505C (zh)	2003-05-07
AU670300B2 (en)	1996-07-11
PT582455E (pt)	2001-03-30
NO950424L (no)	1995-04-06
CA2101572A1 (fr)	1994-02-08
CN1318031C (zh)	2007-05-30
FI115457B (fi)	2005-05-13
ATE197295T1 (de)	2000-11-15
DE122008000034I1 (de)	2008-10-02
NL300347I1 (nl)	2008-07-01
KR950702970A (ko)	1995-08-23
CN1090277A (zh)	1994-08-03
NL300032I2 (nl)	2001-04-02
ES2151897T3 (es)	2001-01-16
FI20040309A7 (fi)	2004-02-27
JPH0780860B2 (ja)	1995-08-30
MY109834A (en)	1997-08-30
WO1994003440A1 (fr)	1994-02-17
DZ1707A1 (fr)	2002-02-17
YU49439B (sh)	2006-03-03
UA42699C2 (uk)	2001-11-15
LU91446I2 (fr)	2008-07-28
NO950424D0 (no)	1995-02-06
FI950508A0 (fi)	1995-02-06
KR100272387B1 (ko)	2000-11-15
RU95107403A (ru)	1996-11-20
JPH06184124A (ja)	1994-07-05
MX9304775A (es)	1994-05-31
AU4449693A (en)	1994-02-10
RO113641B1 (ro)	1998-09-30
HRP931102B1 (en)	2001-06-30
BG99383A (bg)	1995-09-29
LV12719A (lv)	2001-09-20
MX192812B (es)	1999-07-30
IL106507A (en)	1997-11-20
HUT71219A (en)	1995-11-28
CA2101572C (fr)	2001-08-28
TWI233436B (en)	2005-06-01
RU2186775C2 (ru)	2002-08-10
FI950508L (fi)	1995-02-06
CN1250652A (zh)	2000-04-19
SK16195A3 (en)	1995-07-11
NO304886B1 (no)	1999-03-01
CZ28695A3 (en)	1995-09-13
NO2000004I1 (no)	2000-06-16
DE69329608D1 (de)	2000-12-07
YU53093A (sh)	1996-10-09
IL106507A0 (en)	1993-11-15
DE10199013I1 (de)	2001-05-23
SK282276B6 (sk)	2002-01-07
CZ290447B6 (cs)	2002-07-17
HU223076B1 (hu)	2004-03-01
NL300032I1 (fr)	2001-02-01
GR3034754T3 (en)	2001-02-28
PL176679B1 (pl)	1999-07-30
DE10199013I2 (de)	2007-05-24
HK1009267A1 (en)	1999-05-28
PL307348A1 (en)	1995-05-15
CN1051767C (zh)	2000-04-26
PL175615B1 (pl)	1999-01-29
DE69329608T2 (de)	2001-05-03
HU9500366D0 (en)	1995-03-28

Publication	Publication Date	Title
US5665720A (en)	1997-09-09	Benzoxazinones as inhibitors of HIV reverse transcriptase
AU670300B2 (en)	1996-07-11	Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (fr)	1995-08-03	Benzoxazinones en tant qu'inhibiteurs de transcriptase inverse du vih
US5633405A (en)	1997-05-27	Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
KR102695633B1 (ko)	2024-08-14	피리미딘을 포함하는 테트라하이드로이소퀴놀린 유도체 및 이의 결핵 치료제 용도
HK1009267B (en)	2001-05-25	Benzoxazinones as inhibitors of hiv reverse transcriptase
CZ289176B6 (cs)	2001-11-14	Farmaceutický prostředek pro inhibici reverzní transkripce HIV
PL176649B1 (pl)	1999-07-30	Kombinacja związków farmakologicznie czynnych do zapobiegania infekcji HIV lub leczenia infekcji HIV lub leczenia AIDS albo ARC